Sign Up for a Free Account

Evidence-based medicine measures calculated from published trials of interferon beta in relapsing-remitting multiple sclerosis or first clinically isolated syndromes suggesting multiple sclerosis

Risk ratio (RR), absolute risk reduction (ARR) of adverse outcomes (conversion to clinically defined multiple sclerosis, relapse, progression, or MRI activity), and numbers needed to treat (NNT) to prevent the adverse outcomes have been calculated for the multicenter randomized controlled trials (references indicated between parenthesis in table second row) according to intention-to-treat analysis principles (patients lost to follow-up or who stopped treatment taken as adverse outcomes, if not differently reported) on 2-year results except when indicated. (Contributed by Dr. Luca Durelli.)

Related Media